STA
NVO

Smith Thornton Advisors’s Novo Nordisk NVO Stock Holding History

Smith Thornton Advisors’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$227K Buy
+4,615
New +$198K 0.1% 126
2024
Q3 		– Sell
-1,583
Closed -$226K – 138
2024
Q2 		$226K Buy
+1,583
New +$210K 0.17% 118

Other funds holding NVO

SRIM
Saratoga Research & Investment Management Saratoga, California $1.83B AUM 18.41% 1-Year Est. Return
SAM
Simplify Asset Management Las Vegas, Nevada $7.19B AUM 6.88% 1-Year Est. Return
GA
GuoLine Advisory Singapore $1.07B AUM 26.27% 1-Year Est. Return
QI
QV Investors Calgary, Alberta, Canada $1.3B AUM 31.14% 1-Year Est. Return
AA
ABC Arbitrage Paris, France $926M AUM 45.9% 1-Year Est. Return
OFA
Oak Family Advisors Chicago, Illinois $391M AUM 26.35% 1-Year Est. Return
PM
Penbrook Management New York $157M AUM 46.57% 1-Year Est. Return
PFS
Prospera Financial Services Dallas, Texas $6.89B AUM 37.41% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
AIP
ARS Investment Partners New York $2.29B AUM 113.95% 1-Year Est. Return

Smith Thornton Advisors's NVO Position: Q2 2026 in Review

Smith Thornton Advisors opened a new position in Novo Nordisk (NVO) in Q2 2026: 4,615 shares worth $227K. The stake represents 0.1% of the portfolio and ranks #126 among its holdings. This is a return to the name: Smith Thornton Advisors previously reported a position in NVO as recently as Q2 2024.

Smith Thornton Advisors first reported a position in NVO in Q2 2024 and has held it in 2 quarters since. 387 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Smith Thornton Advisors held 4,615 shares of Novo Nordisk worth $227K as of Q2 2026.
  • Novo Nordisk was a new Smith Thornton Advisors position in Q2 2026.
  • Novo Nordisk made up 0.1% of Smith Thornton Advisors's portfolio in Q2 2026, its #126 holding.
  • Smith Thornton Advisors first reported a position in Novo Nordisk in Q2 2024 and has held it in 2 quarters since.
  • 387 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Smith Thornton Advisors's 13F filing for Q2 2026, filed 14 Jul 2026.